Risk factors of Asherman's syndrome

Clinical, reproductive, and immunological aspects of patients with Asherman's syndrome

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN14987772

Enrollment

Registered

2021-03-15

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asherman's syndrome Urological and Genital Diseases Asherman's syndrome, intrauterine synechiae

Interventions

After enrolment, a detailed medical history will be taken and during the indicated hysteroscopy, an endometrial biopsy will be collected for single-cell analysis. Standard medical care follows. Every

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Clinical suspicion of Asherman's syndrome verified by hysteroscopy or previous intrauterine procedure with follow-up hysteroscopy without intrauterine adhesions

Exclusion criteria

Exclusion criteria: 1. Other uterine pathology (e.g. submucosal leiomyoma, adenomyosis, and cervical lesion) 2. Hormonal therapy <1 month prior to the hysteroscopy 3. Gynecological malignancy in last 12 months

Design outcomes

Primary

Measure	Time frame
Characteristics of endometrial reactivity to insult measured using single-cell analysis during the indicated hysteroscopy at baseline	—

Secondary

Measure	Time frame
Reproductive outcomes of patients with Asherman's syndrome measured using questionnaires at baseline, 6, 12, 18, 24, 30, and 36 months	—

Countries

Czech Republic

Contacts

Public ContactBarbora Boudová

barbora.boudova@vfn.cz+420 224967004

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026